Neurocrine Biosciences, Inc.

What they do

Neurocrine discovers, develops, and commercializes treatments for neurological, psychiatric, endocrine, and immunological disorders. Its commercial products include INGREZZA (valbenazine) for tardive dyskinesia and Huntington's disease chorea, CRENESSITY (crinecerfont) for classic congenital adrenal hyperplasia, and VYKAT XR (diazoxide choline) for Prader-Willi syndrome hyperphagia, acquired in May 2026. The company sells INGREZZA through a limited specialty network and CRENESSITY through a single specialty pharmacy, relying on third-party manufacturers for production.

Revenue drivers

• INGREZZA (valbenazine) — The primary revenue driver, with net product sales of $2.51 billion in 2025 and $716 million in Q2 2026 (15% year-over-year growth), used for tardive dyskinesia and Huntington's disease chorea.
• CRENESSITY (crinecerfont) — First-in-class treatment for classic congenital adrenal hyperplasia, launched December 2024; net product sales were $301.2 million in 2025 and $184 million in Q2 2026 (247% year-over-year growth).
• VYKAT XR (diazoxide choline) — Added via the Soleno Therapeutics acquisition completed May 18, 2026; Q2 2026 sales of $54 million from the closing date, with pro-forma full quarter sales of $94 million.
• Collaboration revenues — Small component ($4.7 million in Q2 2026) from partnerships such as AbbVie for elagolix (endometriosis and uterine fibroids).

Recent performance

Total Q2 2026 revenue grew 39% year-over-year to $959 million, with net product sales of $954.3 million. Net income for Q2 2026 was $144.4 million (diluted EPS $1.39), up from $107.5 million (diluted EPS $1.06) in Q2 2025. For the six months ended June 30, 2026, revenue was $1.77 billion and net income was $342.3 million. As of June 30, 2026, total assets were $5.36 billion, shareholder equity was $3.69 billion, and cash plus available-for-sale debt securities totaled $481.7 million, down from $713.0 million cash at year-end 2025 due to the Soleno acquisition.

Strategy

Management plans to maximize INGREZZA and CRENESSITY through expanded sales teams (announced October 2025, expected complete by Q1 2026) and to develop valbenazine as best-in-class for new patient populations, while leading VMAT2 biology. The company is investing in a late-stage pipeline including osavampator for major depressive disorder and direclidine for schizophrenia, with Phase 3 readouts expected in 2027. It also aims to leverage the Soleno acquisition to strengthen its endocrinology and rare disease franchise.

Risks

• Commercial reliance on INGREZZA — INGREZZA accounts for a significant portion of revenue; if growth slows or competition intensifies, results could be harmed.
• CRENESSITY launch execution — The product is in its early launch phase; if patient uptake or reimbursement does not meet expectations, revenue may fall short.
• Regulatory and pricing pressures — Healthcare reforms, including the Inflation Reduction Act, and government/third-party payor pricing controls could limit coverage or reimbursement and reduce revenues.
• Pipeline and clinical trial uncertainties — Product candidates may fail in clinical trials or face delays, potentially preventing or delaying regulatory approval and future growth.

Outlook

Management raised full-year 2026 INGREZZA net sales guidance to $2.825–$2.875 billion, up from $2.7–$2.8 billion. They expect to complete the sales force expansion by the end of Q1 2026 and anticipate multiple clinical milestones in 2027, including Phase 3 readouts for osavampator and direclidine. The company also highlighted new data supporting CRENESSITY's long-term benefits and VYKAT XR's efficacy.